Trade Names:Unasyn- Powder for injection 1.5 g (1 g ampicillin sodium per 0.5 g sulbactam sodium)- Powder for injection 3 g (2 g ampicillin sodium per 1 g sulbactam sodium)- Powder for injection 10 g (10 g ampicillin sodium per 5 g sulbactam sodium)
Ampicillin inhibits bacterial cell wall mucopeptide synthesis. Sulbactam inhibits plasmid-medicated beta-lactamase enzymes commonly found in microorganisms resistant to ampicillin.
Treatment of infections of skin and skin structure, intra-abdominal and gynecologic infections caused by susceptible microorganisms, and mixed infections caused by ampicillin-susceptible organisms and beta-lactamase–producing organisms.
Hypersensitivity to penicillins, cephalosporins, or imipenem.
IV/IM 1.5 to 3 g every 6 h, not to exceed 4 g/day sulbactam (1.5 g of product contains 0.5 g sulbactam).Children 1 yr of age or older (less than 40 kg)
IV 300 mg/kg/day (200 mg ampicillin/100 mg sulbactam) in divided doses every 6 h.Children at least 40 kg
IV Dose according to adult recommended doses; do not exceed total sulbactam dose of 4 g/day.
Keep refrigerated after reconstitution. Medication is stable for 2 h at room temperature, 72 h if refrigerated. Store at or below 86°F prior to reconstitution.
Increases potential for ampicillin-induced skin rash.Contraceptives, oral
May reduce efficacy of oral contraceptives.Tetracyclines
May impair bactericidal effects of ampicillin/sulbactam.
Do not mix with aminoglycosides (eg, gentamicin).
May cause false-positive urine glucose test results with Benedict solution, Fehling solution, or Clinitest tablets (enzyme-based tests; eg, Clinistix , Tes-tape , are recommended); false-positive direct Coombs test result in certain patient groups; false-positive protein reactions with sulfosalicylic acid and boiling test, acetic acid test, biuret reaction and nitric acid test (the bromphenol blue test, Multistix , is recommended).
Thrombophlebitis at injection site.
Dizziness; fatigue; insomnia; reversible hyperactivity.
Urticaria; maculopapular to exfoliative dermatitis; vesicular eruptions; erythema multiforme; skin rashes.
Itchy eyes; laryngospasm; laryngeal edema.
Diarrhea; pseudomembranous colitis.
Interstitial nephritis (eg, oliguria, proteinuria, hematuria, hyaline casts, pyuria); nephropathy; increased BUN and creatinine; vaginitis.
Decreased Hgb, Hct, RBC, WBC, neutrophils, lymphocytes, platelets; increased lymphocytes, monocytes, basophils, eosinophils, and platelets.
Elevated serum alkaline phosphatase, glutamic oxaloacetic transaminase, ALT, AST, and LDH; reduced serum albumin and total proteins.
Pain at injection site; hyperthermia.
Category B .
Excreted in breast milk.
Safety and efficacy not established.
Reactions range from mild to life-threatening. Use cautiously in cephalosporin-sensitive patients because of possible cross-allergenicity.
Use cautiously with altered dosing interval.
May result in overgrowth of nonsusceptible bacterial or fungal organisms.
Hyperexcitability, convulsive seizures.
Copyright © 2009 Wolters Kluwer Health.